Just Released - Transplantation - August 2023 Issue

In this month's issue there is an important dissection of the diagnosis of death in the context of in-situ normothermic thoracic perfusion, which together with analysis of pre-mortem donor interventions provides much food for thought. Elsewhere in the issue lung transplants, tracheal transplantation, pulmonary complications in liver transplantation and ddcfDNA in kidney transplantation are well reviewed.

Table of Contents

Around the World

Research Highlights

People in Transplantation

Expert Insight

Special Article

Reviews



World Day Against Trafficking in Persons


Upcoming Webinar Presentation


Transplantation - Highlighted Tweets

Multimodal Transplant-clinic–based Skin Cancer Prevention Education for Organ Transplant Recipients: Feasibility Study
We studied the feasibility of transplant-clinic staff routinely providing primary prevention advice to lung transplant recipients at high risk of skin cancer.
Cognitive Outcome After Islet Transplantation
Severe or repeated hypoglycemia events may favor memory complaints in type 1 diabetes (T1D). Pancreatic islet transplantation (IT) is an alternative option to exogenous insulin therapy in case of labile T1D, implying a maintenance immunosuppression regimen based on sirolimus or mycophenolate, associated with tacrolimus, that may also have neurological toxicity. The objective of this study was to compare a cognitive rating scale Mini-Mental State Examination (MMSE) between T1D patients with or without IT and to identify parameters influencing MMSE.

Transplantation Direct - Highlighted Tweets

Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study
The comparative impact of everolimus (EVR)-based regimens versus standard of care (mycophenolic acid+standard calcineurin inhibitor [MPA+sCNI]) on cardiovascular outcomes in de novo kidney transplant recipients (KTRs) is poorly understood. The incidence of major adverse cardiac events (MACEs) in KTRs receiving EVR+reduced CNI (rCNI) or MPA+sCNI from the TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen study was evaluated.
Physiological Age by Artificial Intelligence–Enhanced Electrocardiograms as a Novel Risk Factor of Mortality in Kidney Transplant Candidates
Mortality risk assessment before kidney transplantation (KT) is imperfect. An emerging risk factor for death in nontransplant populations is physiological age as determined by the application of artificial intelligence to the electrocardiogram (ECG). The aim of this study was to examine the relationship between ECG age and KT waitlist mortality.

Reminder 2023 Proposed TTS By-law Changes

Deadline to submit your ballot is October 21, 2023

TTS Council is pleased to present eight proposed By-law amendments to aid in shaping the future of the Society.
Among the changes proposed are expansion of Council to increase diversity; ensuring female, early career and Middle East AND Africa countries representation.

To review the proposed by-law amendments and the rationale statements please click the link below.
If you are a TTS full member you should have received a message with your personalized voting link today. Alternatively you may also use the link above to review the amendments and submit ballot.

ISUTx 2023 - Submit Your Abstract Today!

Abstract Submission Deadline: August 4

ISUTx is delighted to announce that abstract submission for its 4th International Congress on uterus transplantation is now open!


SPLIT 2023 - Submit Your Abstract Today!

Abstract Submission Deadline: August 15

We plan on welcoming leading experts and opinion leaders from all over the world to present their latest data and address important needs in clinical pediatric liver transplant and hosting sessions devoted to emerging research in the field.


In the News 


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada